EHAVE, Inc.

EHVVF

CA28238M2058

IT Services & Consulting

Market Closed - OTC Markets Other stock markets 03:56:51 2024-04-26 pm EDT			5-day change	1st Jan Change
0.001 ^USD	0.00%		0.00%	+233.33%

2023	Ei.Ventures, Inc. cancelled the acquisition of Mycotopia Therapies Inc. from EHAVE, Inc. (OTCPK:EHVV.F) and others in a reverse merger transaction.	CI
2022	FDA Grants EHAVE, Inc. Consent to Proceed with Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder	CI

Ehave, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

May 28, 2021 at 06:23 am EDT

EHAVE, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 2.046 million compared to USD 411,019 a year ago. Net loss was USD 3.514 million compared to USD 3.637 million a year ago. Basic loss per share was USD 0.11 compared to USD 0.18 a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.03 a year ago.

Latest news about EHAVE, Inc.

Ei.Ventures, Inc. cancelled the acquisition of Mycotopia Therapies Inc. from EHAVE, Inc. (OTCPK:EHVV.F) and others in a reverse merger transaction.	23-02-15	CI
FDA Grants EHAVE, Inc. Consent to Proceed with Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder	22-12-15	CI
EHAVE, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-27	CI
EHAVE, Inc. Auditor Raises 'Going Concern' Doubt	22-05-26	CI
EHAVE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	22-05-23	CI
Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ	22-05-23	CI
Ehave, Inc. Announces MetaHealthU Will Enter The Market With A Focus On HPPD	22-04-19	CI
Ehave, Inc. Continues Expansion Of KetaDASH Mobile Psychedelic Service By Providing Licensed Psychotherapists And Registered Nurses	22-03-03	CI
EHAVE, Inc. (OTCPK:EHVV.F) completed the acquisition of Rejuv IV Inc.	22-02-08	CI
EHAVE, Inc. announced that it has received $0.8327 million in funding	21-09-29	CI
Ehave, Inc. Announces Rahul Dixit to the Company's Medical Advisory Board	21-09-21	CI
Ehave, Inc. Announces Update on Ehave Medical App with the Launch of Covid Vaccine Passport Going Live Shortly	21-09-07	CI
EHAVE, Inc. (OTCPK:EHVV.F) agreed to acquire Tennessine Software Trading LLC.	21-08-23	CI
EHAVE, Inc. (OTCPK:EHVV.F) signed a Letter of Intent to acquire Moksha Digital Software Pvt. Ltd.	21-08-23	CI
Ehave Acquires License Covering G-20 Countries for All Psychedelic Use, AI-Powered Telehealth Technology to Capture Physiological Vitals from Vastmindz; Prepares to Run Testing on Dashboard	21-08-11	CI
EHAVE, Inc. Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder	21-08-04	CI
Ehave, Inc. Announces Plans to Launch A Series of Studies to Determine the Cause and Possible Cure for Hallucinogen-Persisting Perception Disorder	21-07-29	CI
Ehave, Inc. Appoints Bankole A. Johnson as Medical Advisory Board	21-07-06	CI
EHAVE, Inc. Announces Dr. Muneer A. Ali Joined the Company’s Medical Advisory Board	21-07-01	CI
Ehave, Inc. Announces Appointment of Nitin Desai as Medical Advisory Board	21-06-29	CI
Ehave, Inc. Announces the Appointment of Jeffrey D. Kamlet to the Position of Chief Medical Officer	21-06-15	CI
Ehave Expands Dashboard Capabilities to Include Decentralized Trials and Virtual Studies	21-06-02	CI
EHAVE, Inc Provides Information to Shareholders	21-05-28	CI
Ehave, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-28	CI
EHAVE, Inc. Auditor Raises 'Going Concern' Doubt	21-05-27	CI

Chart EHAVE, Inc.

Duration

Period

More charts

Company Profile

Ehave, Inc. is a Canada-based company, which is an engaged in the digital therapeutics delivering evidence-based therapeutic interventions to patients. The Companyâs primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. The Companyâs main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make decisions through data insights. The Companyâs Ehave Infinity Portal offers a machine learning and artificial intelligence platform with a growing set of tools and applications developed by the Company and its partners. This enables patients, healthcare providers and payers to address a range of conditions through data-driven involvement with the tools.

Sector

IT Services & Consulting

More about the company

Sector Other IT Services & Consulting

	1st Jan change	Capi.
EHAVE, INC.	+233.33%	360K
ACCENTURE PLC	-13.61%	194B
TATA CONSULTANCY SERVICES LTD.	+2.02%	166B
IBM	+2.37%	153B
AUTOMATIC DATA PROCESSING, INC.	+4.71%	99.85B
RELX PLC	+5.88%	77.56B
CROWDSTRIKE HOLDINGS, INC.	+19.08%	73.55B
INFOSYS LIMITED	-7.01%	71B
SNOWFLAKE INC.	-20.88%	52.81B
HCL TECHNOLOGIES LIMITED	-5.37%	47.86B

Other IT Services & Consulting

EHAVE, Inc.

Equities

EHVVF

CA28238M2058

IT Services & Consulting

Ehave, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

Latest news about EHAVE, Inc.

Chart EHAVE, Inc.

Company Profile

Sector Other IT Services & Consulting